Op-Ed: There’s a Major Obstacle to Finding The Cure for Alzheimer’s

This article originally appeared in Daily Caller on March 4, 2023

 

Three years ago, one of us (Carter) co-authored an op-ed projecting that the fiscal and humanitarian costs from a single disease, Alzheimer’s (AD), if left unchecked, would be ruinous. Last year, the other one of us (Pinkerton) authored an op-ed arguing that the U.S. Food and Drug Administration (FDA) was a hindrance to medical progress on this disease.

Now we are writing together to declare that the fiscal risk is worsening, and the FDA is still blocking it. According to the Alzheimer’s Association, AD costs the U.S. $321 billion annually, and the cost — to say nothing of the human pain — is projected to rise steadily. As a result, something must change. Everyone should hope that the “something” is a scientific breakthrough in AD that improves lives and lowers costs. After all, it’s cheaper to beat than to treat; a cure is better than care...

Read full op-ed in Daily Caller